Targeting ErbB3 Receptor in Cancer with Inhibitory Antibodies from Llama

The human ErbB3 receptor confers resistance to the pharmacological inhibition of EGFR and HER2 receptor tyrosine kinases in cancer, which makes it an important therapeutic target. Several anti-ErbB3 monoclonal antibodies that are currently being developed are all classical immunoglobulins. We took a...

Descripción completa

Detalles Bibliográficos
Autores principales: Eliseev, Igor E., Ukrainskaya, Valeria M., Yudenko, Anna N., Mikushina, Anna D., Shmakov, Stanislav V., Afremova, Anastasiya I., Ekimova, Viktoria M., Vronskaia, Anna A., Knyazev, Nickolay A., Shamova, Olga V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467012/
https://www.ncbi.nlm.nih.gov/pubmed/34572289
http://dx.doi.org/10.3390/biomedicines9091106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467012/
https://www.ncbi.nlm.nih.gov/pubmed/34572289
http://dx.doi.org/10.3390/biomedicines9091106

Ejemplares similares